Article · Volume 14, Issue 2 · pp. 706-736
Bibliometric Analysis to Explore Trends of the 100 Most Cited Articles in Population Pharmacokinetic and/or Pharmacodynamic Modelling
Nur Mardhiya Darnalis1,2, Hadzliana Zainal2, Eva Germovsek3
- 1Department of Pharmacy, Hospital Kulim, Kedah, MALAYSIA.
- 2School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, MALAYSIA.
- 3Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH and Co. KG, Ingelheim, GERMANY.
Abstract
Population pharmacokinetic and/or pharmacodynamic [PK(/PD)] modelling has become more popular in drug development and academic research. However, there are no reports exploring the research trends in this area. To explore the (research) trends of most cited articles on PK(/PD) modelling, we bibliometrically analysed the most cited articles (n=100) extracted from the Scopus online database from inception (1964-2021) and again in the recent years (2015-2021) using VOSviewer v1.6.15 and Publish or Perish v8 software. Information such as ATC/drug class, model type, software used, studied population, authors’ institutions, journals, collaborations between countries, and funding sources was extracted and compared. Majority of the studies (65%) described in the 100 most cited articles were population PK modelling studies, with the proportion of the population PKPD modelling studies increasing over time (from 30 to 43%). A large percentage of the impactful articles (43%) were published by top five journals, analysed adult data (84%) and used NONMEM® (80%), which has not changed much over time. Most of the impactful articles studied chemotherapeutic and immunomodulating (33%), anti-infective (29%), and central nervous system (22%) ATC class of drugs, with articles analysing immunosuppressant drug class increasing the most over time (from 10% to 18%). In conclusion, we used a bibliometric approach and investigated research trends in top 100 most cited articles involving PK (/PD) modelling. Apart from the changes mentioned above most other metrics that we compared remained relatively unchanged over time.
Keywords: Keywords; POPPK; Nonlinear mixed effect model; Citation analysis; NONMEM
FULL TEXT
INTRODUCTION
Understanding the dose-concentration-effect relationship is a fundamental concept in clinical pharmacology. Mathematical and statistical models are often used to help describing the above mentioned relationship.[1] More specifically, such models are: population pharmacokinetic (PK) models [to describe the relationship between drug dose and concentration], pharmacodynamic (PD) models [to describe the time course of the biomarkers/safety/efficacy], and pharmacokinetic-pharmacodynamic (PKPD) models [incorporates both PK and PD to describe the relationship between drug dose and/or concentration and effect].[2] PKPD modelling and simulation (M&S) plays an important role in drug development and is promoted by the regulatory agencies, including the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) to improve efficiency and productivity in pharmaceutical drug development.[3–5]
Several methods for determining drug population pharmacokinetics have been proposed, such as the naïve average data approach, naïve pooled data analysis, a two-stage approach, and a Nonlinear Mixed-Effects (NLME) modelling approach.[6] Human patients differ from one another, therefore their drug disposition and pharmacodynamic effects are heterogenous. To be able to describe the PK (and PD) parameters without bias, an approach that does not over- or underestimate such between patient variability is needed. Comparing the above-mentioned modelling approaches, the mixed-effects modelling approach provides estimates of such variability that are more accurate and less biased.[6] The NLME approach is implemented in many general and specialised statistical tools[7, 8] and it is the most widely used population-based modelling,[9, 10] possibly due to its advantage of being able to handle sparse and unbalanced data (i.e. data where the number of observations and/or sampling times differs between individuals) better compared to other approaches. Furthermore, an NLME model can quantitatively describe the effects of covariates (e.g., sex, age, body weight) on the PK data.[11, 12] Thus, this study only focused on the analyses that used the NLME approach.
Bibliometric analysis is a scientific technique that identifies central concepts, emerging trends, and areas of study interest in certain subjects or research domains by fusing statistical techniques with information visualisation technologies.[13] Citation counts have long been used to assess the quality of research articles and the contributions and scientific performance of scientists, research groups, departments, and universities. These data have been frequently used to make, for example, key policy, performance, career advancement, award selection, and funding decisions.[14] Furthermore, bibliometric analysis allows researchers to identify key study topics and explore the trends in a field, and thus providing ideas and directions for future research.[15]
Hitherto, there has been no bibliometric analysis or other analysis, focusing also on the research trends of most cited articles in the population PK, PD, or PKPD modelling. Hence, we designed a bibliometric study to analyse the top 100 most cited articles since inception (1964-2021) and in the recent years (2015-2021) to explore the trends of most cited papers using data from the Scopus database.
METHODOLOGY
Available data
Information on the 100 most cited articles on population NLME PK (/PD) modelling since inception and in the recent years was obtained from the Scopus online database. The search for articles on population modelling, specifically PK or PD or PKPD modelling studies, was restricted to the article title, abstract, keywords, and studies published by the end of 2021. The Scopus database was accessed in February 2022, to perform searches for overall top 100 most cited articles, and again in August 2022, to search for publications published between 2015-2021. The following query string was used: TITLE-ABS-KEY ("population pharmacokinetic* model*" OR “pharmacokinetic* model*" OR "population pharmacokinetic*" OR "population pharmacodynamic*" OR "pharmacodynamic* model*" "pharmacokinetic* pharmacodynamic* model*" OR "nonlinear mixed effect* model*") AND PUBYEAR < 2022.
Key data from the Scopus database were merged with data from manual search approaches to ensure data accuracy and comprehensiveness. Information collected from the Scopus database included the article’s title, abstract, keywords, publication year, publication types, the number of citations, name of authors, authors’ countries, organisations, journals, and funding. Furthermore, information from journal quartiles and Anatomical Therapeutic Chemical (ATC) Classification were retrieved manually to supplement the Scopus information. In this regard, we referenced the SCImago Journal Rank (SJR) 2021 edition[16] to determine journal quartiles, while the therapeutic class was identified based on the Anatomical Therapeutic Chemical (ATC) Classification system at the first (main anatomical group) and second level (drug classes).
Each publication was reviewed to ensure that the study refers to the population PK or PD or PKPD modelling rather than other fields like software development. Full texts of the articles were retrieved where necessary.
The full inclusion criteria are outlined below:
- Original articles related to the development, evaluation or validation, and application of population pharmacokinetic and/or pharmacodynamic models.
- Population data were analysed using a Nonlinear Mixed Effect (NLME) modelling approach.
The exclusion criteria included reviews, methodology articles, and preclinical in vitro and in vivo studies. Figure 1 describes the selection process for the years 1964-2021 and Supplementary Figure 1 describes the selection process for the years 2015-2021 based on the PRISMA 2009 flow diagram.[17] No ethics approval was required since this study was a bibliometric analysis with no human/animal subjects involved.
Bibliometric and Visualisation Analysis
Harzing’s Publish or Perish software v8 was used to import data from the Scopus database to determine each article’s citations per year. To map and visualise the co-authorship relationship between countries of the authors we produced network maps via VOSviewer 1.6.15 software (www.vosviewer.com).
RESULTS
Characteristics of the 100 most cited population PK, PD, or PKPD modelling
The number of citations ranged from 137 to 914 and 37 to 156 for the 100 most cited articles since inception and in the recent years, respectively. Most of the 100 most cited articles since inception were published in 2008 (n=10) involving anti-infectives, central nervous system agents, and chemotherapeutics and immunomodulating agents, while most articles in the recent years were published in 2015 (n=45) with a similar scope of studies. The Supplementary Table 1 lists the 100 most cited articles on population PK, PD, or PKPD modelling since inception to 2021 based on the number of citations in descending order. Meanwhile, the most cited articles published 2015-2021 are listed in Supplementary Table 2.
The article “Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil I. Model development”[18] has the highest number of total citations since inception until 2021 (n=914). Whereas “Population pharmacokinetics of colistin methane sulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients”[19] has the highest citation rate per year with an average of 48.82 citations per year (Supplementary Table 1). Eighty-eight percent of the 100 most cited articles since inception were published in Quartile 1 journals, which increased to 91% in recent years.
Anatomical therapeutic classification groups/drug classes
The most studied ATC class of drugs in the top 100 most cited articles were chemotherapeutics and immunomodulating agents (33%), with anti-infectives (29%) and central nervous system ATC class (22%) represented similarly in the second and third place (Figure 2). In the recent 100 most cited articles the trends remained similar, with the number of studies analysing the chemotherapeutic and immunomodulating agents, and anti-infective ATC drug class increasing (42% and 39%, respectively) whereas the number of central nervous system ATC class reduced (9%). Detailed information on each ATC group and the respective drug classes is summarised in Figure 2.
Antineoplastic agents (23%), antibacterials (13%) and anaesthetics (11%) were the top 3 drug classes in the 100 most cited articles since inception. However, the percentage of influential papers publishing antibacterial modelling results increased recently to 20%, with antineoplastic agents staying relatively the same (24%) and increasing to third place is immunosuppressant drugs (18%) (Figure 2). Detailed information for these drug classes is listed in Supplementary Tables 3-5. The most significant changes within the impactful articles reporting results on antineoplastic, antibacterial, and immunosuppressant drug classes are summarised below, other than that there have not been any major research trend changes. The proportion of studies in paediatric population increased in all the three drug classes. Additionally, most antibacterial studies shifted from polymyxins (42%) to glycopeptide antibiotics (37%) in the recent years (Supplementary Table 4) and for immunosuppressant drugs the trend changed from tumour necrosis factor-alpha inhibitors (44%) to selective immunosuppressants (53%) (Supplementary Table 5).
Type of study, investigated population and software used
Most of the studies described in the top 100 most cited articles were population PK studies (65%) followed by population PKPD modelling studies (30%) (Table 1). Recently, the number of population PK modelling studies decreased (55%) and the number of populations PKPD modelling studies increased (43%). PD studies represented only ≤5% of the studies throughout the years (Table 1).
The classification of PKPD modelling study was determined if the article used at least one population PK and/or PD model, e.g. a study of population PK, combined with a PKPD metric for the PD part was counted as a PKPD modelling study.
Majority of the impactful articles reported analyses of the adult population compared to the paediatric populations (Table 2), with only a small increase in the percentage (1%) of studies performed in the paediatric population in recent years. In the 100 most cited articles since inception most paediatric studies included children over 2 years (7 out of 12 paediatric studies), however, recently, most studies (6 out of 13 paediatric studies) included a wide distribution of paediatric ages (i.e. from newborn until adolescent) (Table 2).
Eighty percent of the top 100 most cited articles in all publications used NONMEM® software to analyse the PK(/PD) data. Interestingly, this number recently increased (83%) confirming that NONMEM® is still the main software for population analyses (Table 3). Within the most cited research, only a few researchers used different types of software besides NONMEM®, such as, S-ADAPT, NLME, Phoenix NLME, Monolix, SAS software, NPEM2 and NLMIXED (Table 3).
Number of authors, institutions and journals, collaborations, and funding sources
The number of authors ranged from 1 to 20 (median 8 authors) and 3 to 32 (median 9 authors) for the 100 most cited publications and the top 100 most cited publications in recent years, respectively.
Table 4 shows the top six institutions that were affiliated with authors who published the 100 most cited population PK, PD or PKPD modelling analyses. Out of these, three institutions were from the European Union and two were from the US, however, recently, 5 out of the top 6 institutions (except University of Queensland) were from Europe. The institution that contributed the most to the 100 most cited articles since inception was Uppsala University (8%), but recently, University of Liverpool and Leiden University Medical Center both contributed as much as Uppsala University (6%) (Table 4).
The 100 most cited articles were published in 39 academic journals and 38 academic journals for overall years and recent years, respectively. The majority of these impactful articles since inception were published in Anesthesiology, however, recently, the impactful research has been mostly published in Antimicrobial Agents and Chemotherapy (Table 5). Top 5 journals that published more than 40% of the 100 most cited articles since inception and in recent years, remained mostly unchanged over time. Nevertheless, in the recent years, Clinical Pharmacokinetics entered the top 5, replacing Anesthesiology. Detailed information on the top journals and their SCImago Journal Ranking (SJR) value is given in Table 5.
Co-authorship network analyses showed that the circle representing United States was the largest indicating the most publications (Figures 3 and 4). United States also had the highest total link strength of 54 (Table 6) which even increased recently (to 65), making USA the most prominent collaborating country. The Netherlands and United Kingdom remained in the top three most prominent countries. The collaboration between countries has, however, changed slightly over time. In the overall 100 most cited articles researchers collaborated most with and between developed countries, such as, United States and Germany or Sweden (Figure 3), but recently, an increasing number of researchers from developing countries (such as South Africa and China) collaborated with those from a developed country (Figure 4).
Table 7 summarises the funding status for the 100 most cited articles. Unfortunately, not all publications reported the founding source: in the top 100 most cited publications 20 did not report it, however, this improved with time (to n=7). More than 70% of the studies received funding locally since inception, but in the top 100 most cited articles published recently, there was a slight increase (2%) of international funding (Table 7). As an example, one study from a developing country (South Africa) received funds from the World Health Organization, and the United States Agency for International Development.[21]
| Type of population modelling studies | Percentage of articles | |
|---|---|---|
| 1964-2021 | 2015-2021 | |
| Population Pharmacokinetic (PK) | 65 % | 55% |
| Population Pharmacodynamic (PD) | 5 % | 2 % |
| Population Pharmacokinetic-Pharmacodynamic (PKPD)a | 30 % | 43 % |
| Study population | Percentage of articles | |
|---|---|---|
| 1964 -2021 | 2015-2021 | |
| Adults | 84% | 80% |
| Paediatric patientsa | 12% | 13% |
| Newborns (<1 month) | 1% | - |
| Infants and toddlers (1 month to <2years) | 2% | 3% |
| Children (2-11 years) | 7% | 1% |
| Adolescents (12-18 years) | 1% | 3% |
| More than in 1 subcategory | 1% | 6% |
| Paediatric and adult patients | 4 % | 7 % |
| Type of population modelling software used | Percentage of articles | |
|---|---|---|
| 1964 -2021 | 2015-2021 | |
| NONMEM® | 80 % | 83 % |
| Other software | 18 % | 15 % |
| Pmetrics | 5% | |
| Phoenix NLME | 1% | 4% |
| Monolix | - | 4% |
| NPAG | 3% | - |
| S-ADAPT | 3% | 2% |
| ADAPT2 | 1% | - |
| NLME | 3% | - |
| P-Pharm | 1% | - |
| WinNonMix | 1% | - |
| NPEM | 2% | - |
| NLMIXED | 2% | - |
| SAS | 1% | |
| Software not mentioned | 2% | 2% |
| 1964-2021 | 2015-2021 | ||
|---|---|---|---|
| Institutions | Percentage of articles | Institutions | Percentage of articles |
| Uppsala University, Sweden | 8% | Uppsala University, Sweden | 6% |
| Standford University, United States | 5% | University of Liverpool, United Kingdom | 6% |
| University at Buffalo, United States | 4% | Leiden University Medical Center, Netherlands | 6% |
| Leiden University Medical Center, Netherlands | 4% | Erasmus Medical Centre-Sophia Children's Hospital, Netherlands | 5% |
| University of Queensland, Australia | 4% | University Medical Center Groningen, Netherlands | 5% |
| Erasmus Medical Centre, Netherlands | 3% | University of Queensland, Australia | 5% |
| 1964-2021 | 2015-2021 | ||||
|---|---|---|---|---|---|
| Journal | Percentage of articles | SJR 2021 | Journal | Percentage of articles | SJR 2021 |
| Anesthesiology | 16% | 1.65 | Antimicrobial Agents and Chemotherapy | 14% | 1.55 |
| Antimicrobial Agents and Chemotherapy | 13% | 1.55 | Clinical Pharmacokinetics | 11% | 1.27 |
| Clinical Pharmacology and Therapeutics | 5% | 1.69 | British Journal of Clinical Pharmacology | 9% | 1.06 |
| British Journal of Clinical Pharmacology | 5% | 1.06 | Clinical Pharmacology and Therapeutics | 6% | 1.69 |
| Journal of Clinical Pharmacology | 4% | 0.69 | Journal of Clinical Pharmacology | 4% | 0.69 |
| 1964-2021 | 2015-2021 | ||||
|---|---|---|---|---|---|
| Rank | Country | Total Link strength | Rank | Country | Total Link strength |
| 1 | United States | 54 | 1 | United States | 65 |
| 2 | Netherlands | 35 | 2 | United Kingdom | 46 |
| 3 | United Kingdom | 28 | 3 | Netherlands | 43 |
| 4 | Sweden | 26 | 4 | Switzerland | 28 |
| 5 | Germany | 21 | 5 | Germany | 25 |
| 6 | Canada | 19 | 6 | Sweden | 24 |
| 7 | Switzerland | 13 | 7 | Belgium | 21 |
| 8 | Australia | 10 | 8 | France | 19 |
| 9 | Italy | 10 | 9 | Australia | 17 |
| 10 | Brazil | 7 | 10 | Canada | 10 |
| Funding information | Percentage of articles | |
|---|---|---|
| 1964-2021 | 2015-2021 | |
| Received grant/funding | 74% | 82% |
| Local funding | 23% | 37% |
| Public sector | 50% | 37% |
| Private sector | 1% | 8% |
| Combination of public and private sector | 4% | 6% |
| International funding | 2% | 5% |
| Received no funding | 20% | 7% |
| Funding information not stated | 20% | 7% |
| Rank. | First author | Year | Title | Journal | SCImago Journal Quartile 2021 | Number of citationsa | Citations per year |
|---|---|---|---|---|---|---|---|
| 1. | Minto CF | 1997 | Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil I. Model development | Anesthesiology | Q1 | 914 | 36.56 |
| 2. | Preston SL | 1998 | Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials | Journal of the American Medical Association | Q1 | 585 | 24.38 |
| 3. | Padayatty SJ | 2004 | Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use | Annals of Internal Medicine | Q1 | 579 | 32.17 |
| 4. | Garonzik SM | 2011 | Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients | Antimicrobial Agents and Chemotherapy | Q1 | 537 | 48.82 |
| 5. | Minto CF | 1997 | Pharmacokinetics and pharmacodynamics of remifentanil II. Model application | Anesthesiology | Q1 | 530 | 21.20 |
| 6. | Palmer S | 2008 | Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy | Proceedings of the National Academy of Sciences of the United States of America | Q1 | 509 | 36.36 |
| 7. | Egan TD | 1993 | The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers | Anesthesiology | Q1 | 484 | 16.69 |
| 8. | Plachouras D | 2009 | Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria | Antimicrobial Agents and Chemotherapy | Q1 | 393 | 30.23 |
| 9. | Bruno R | 1998 | Population pharmacokinetics/pharmacodynamics of docetaxel in phase ii studies in patients with cancer | Journal of Clinical Oncology | Q1 | 380 | 15.83 |
| 10. | Scott JC | 1985 | EEG quantitation of narcotic effect: The comparative pharmacodynamics of fentanyl and alfentanil | Anesthesiology | Q1 | 380 | 10.27 |
| 11. | Friberg LE | 2002 | Model of chemotherapy-induced myelosuppression with parameter consistency across drugs | Journal of Clinical Oncology | Q1 | 365 | 18.25 |
| 12. | Avramis VI | 2002 | A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children’s Cancer Group study | Blood | Q1 | 355 | 17.75 |
| 13. | Egan TD | 1996 | Remifentanil versus alfentanil: Comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers | Anesthesiology | Q1 | 345 | 13.27 |
| 14. | Schüttler J | 2000 | Population pharmacokinetics of propofol: A multicenter study | Anesthesiology | Q1 | 332 | 15.09 |
| 15. | Ostermann S | 2004 | Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients | Clinical Cancer Research | Q1 | 326 | 18.11 |
| 16. | Sarton E | 2000 | Sex differences in morphine analgesia: An experimental study in healthy volunteers | Anesthesiology | Q1 | 319 | 14.50 |
| 17. | Rosenfeld MR | 2014 | A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme | Autophagy | Q1 | 309 | 38.63 |
| 18. | Bruhn J | 2000 | Approximate entropy as an electroencephalographic measure of anesthetic drug effect during desflurane anesthesia | Anesthesiology | Q1 | 304 | 13.82 |
| 19. | Ezzet F | 2000 | Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria | Antimicrobial Agents and Chemotherapy | Q1 | 273 | 12.41 |
| 20. | Mueck W | 2011 | Rivaroxaban: Population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention | Clinical Pharmacokinetics | Q1 | 271 | 24.64 |
| 21. | Walsh TJ | 2004 | Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration | Antimicrobial Agents and Chemotherapy | Q1 | 267 | 14.83 |
| 22. | Lu JF | 2008 | Clinical pharmacokinetics of bevacizumab in patients with solid tumors | Cancer Chemotherapy and Pharmacology | Q1 | 264 | 18.86 |
| 23. | Kataria BK | 1994 | The pharmacokinetics of propofol in children using three different data analysis approaches | Anesthesiology | Q1 | 259 | 9.25 |
| 24. | Sandri AM | 2013 | Population pharmacokinetics of intravenous polymyxin B in critically Ill patients: Implications for selection of dosage regimens | Clinical Infectious Diseases | Q1 | 256 | 28.44 |
| 25. | Olofsen E | 2008 | Permutation entropy of the electroencephalogram: A measure of anaesthetic drug effect | British Journal of Anaesthesia | Q1 | 254 | 18.14 |
| 26. | Roberts JA | 2009 | Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: Intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution | Journal of Antimicrobial Chemotherapy | Q1 | 250 | 19.23 |
| 27. | Chatelut E | 1995 | Prediction of carboplatin clearance from standard morphological and biological patient characteristics | Journal of the National Cancer Institute | Q1 | 248 | 9.19 |
| 28. | Liesenfeld KH | 2011 | Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial | Journal of Thrombosis and Haemostasis | Q1 | 246 | 22.36 |
| 29. | Mueck W | 2008 | Population pharmacokinetics and pharmacodynamics of once-and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement | Thrombosis and Haemostasis | Q1 | 246 | 17.57 |
| 30. | Bruno R | 1996 | A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation | Journal of Pharmacokinetics and Biopharmaceutics | n/a | 237 | 9.12 |
| 31. | Fasanmade AA | 2009 | Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis | European Journal of Clinical Pharmacology | Q2 | 235 | 18.08 |
| 32. | Thuresson K | 2006 | Apparent half-lives of hepta- to decabrominated diphenyl ethers in human serum as determined in occupationally exposed workers | Environmental Health Perspectives | Q1 | 235 | 14.69 |
| 33. | Csajka C | 2003 | Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection | Clinical Pharmacology and Therapeutics | Q1 | 231 | 12.16 |
| 34. | Haas DW | 2005 | Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: An adult AIDS clinical trials group study | Journal of Infectious Diseases | Q1 | 227 | 13.35 |
| 35. | Rangwala R | 2014 | Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma | Autophagy | Q1 | 223 | 27.88 |
| 36. | Mueck W | 2008 | Population pharmacokinetics and pharmacodynamics of rivaroxaban - An oral, direct factor Xa inhibitor - In patients undergoing major orthopaedic surgery | Clinical Pharmacokinetics | Q1 | 215 | 15.36 |
| 37. | Kirchheiner | 2003 | Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6 | Pharmacogenetics | n/a | 215 | 11.32 |
| 38. | Kumar SK | 2014 | Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: An open-label phase 1/2 study | The Lancet Oncology | Q1 | 213 | 26.63 |
| 39. | Yacyshyn BR | 2002 | Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn’s disease | Gut | Q1 | 209 | 10.45 |
| 40. | Drusano GL | 2004 | Relationship between fluoroquinolone area under the curve:minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia | Journal of Infectious Diseases | Q1 | 207 | 11.50 |
| 41. | Li C | 2007 | Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections | Antimicrobial Agents and Chemotherapy | Q1 | 202 | 13.47 |
| 42. | Greenberg PL | 2004 | Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995) | Journal of Clinical Oncology | Q1 | 198 | 11.00 |
| 43. | Houk BE | 2009 | A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients | Clinical Cancer Research | Q1 | 197 | 15.15 |
| 44. | Fasanmade AA | 2011 | Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn’s Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials | Clinical Therapeutics | Q2 | 196 | 17.82 |
| 45. | Bruno R | 2005 | Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer | Cancer Chemotherapy and Pharmacology | Q1 | 194 | 11.41 |
| 46. | Carducci MA | 2001 | A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule | Clinical Cancer Research | Q1 | 192 | 9.14 |
| 47. | Kirchheiner J | 2002 | Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers | Clinical Pharmacology and Therapeutics | Q1 | 186 | 9.30 |
| 48. | Stewart MW | 2012 | Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye) | Retina | Q1 | 185 | 18.50 |
| 49. | Rudin CM | 2008 | Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity | Journal of Clinical Oncology | Q1 | 185 | 13.21 |
| 50. | Lu JF | 2006 | Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer | Clinical Pharmacology and Therapeutics | Q1 | 183 | 11.44 |
| 51. | Venn RM | 2002 | Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care | British Journal of Anaesthesia | Q1 | 182 | 9.10 |
| 52. | Anderson BJ | 2002 | Acetaminophen developmental pharmacokinetics in premature neonates and infants: A pooled population analysis | Anesthesiology | Q1 | 182 | 9.10 |
| 53. | Müller C | 2012 | The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL | Blood | Q1 | 181 | 18.10 |
| 54. | Peloquin CA | 1997 | Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide | Antimicrobial Agents and Chemotherapy | Q1 | 181 | 7.24 |
| 55. | Kirchheiner J | 2002 | Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers | Pharmacogenetics | n/a | 179 | 8.95 |
| 56. | Neely M | 2010 | Voriconazole pharmacokinetics and pharmacodynamics in children | Clinical Infectious Diseases | Q1 | 177 | 14.75 |
| 57. | Mertens-Talcott SU | 2008 | Pharmacokinetics of anthocyanins and antioxidant effects after the consumption of anthocyanin-rich açai juice and pulp (Euterpe oleracea Mart.) in human healthy volunteers | Journal of Agricultural and Food Chemistry | Q1 | 176 | 12.57 |
| 58. | Sparr HJ | 2007 | Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: Efficacy, safety, and pharmacokinetics | Anesthesiology | Q1 | 174 | 11.6 |
| 59. | Ezzet F | 1998 | Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients | British Journal of Clinical Pharmacology | Q1 | 174 | 7.25 |
| 60. | Judson I | 2005 | Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: A retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group | Cancer Chemotherapy and Pharmacology | Q1 | 173 | 10.18 |
| 61. | Van Hest RM | 2006 | Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: A population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients | Journal of the American Society of Nephrology | Q1 | 172 | 10.75 |
| 62. | Dotan I | 2014 | Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: A population pharmacokinetic study | Inflammatory Bowel Diseases | Q1 | 171 | 21.38 |
| 63. | Petroz GC | 2006 | A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children | Anesthesiology | Q1 | 170 | 10.63 |
| 64. | Karlsson MO | 2009 | Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies | Antimicrobial Agents and Chemotherapy | Q1 | 169 | 13.00 |
| 65. | Hsu A | 1997 | Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects | Antimicrobial Agents and Chemotherapy | Q1 | 168 | 6.72 |
| 66. | Maitre PO | 1987 | Population pharmacokinetics of alfentanil: The average dose-plasma concentration relationship and interindividual variability in patients | Anesthesiology | Q1 | 168 | 4.80 |
| 67. | Pascual A | 2012 | Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: Population pharmacokinetics-based analysis of adult patients with invasive fungal infections | Clinical Infectious Diseases | Q1 | 166 | 16.60 |
| 68. | Zhou H | 2007 | Pharmacokinetics and safety of golimumab, a fully human anti-TNF-α monoclonal antibody, in subjects with rheumatoid arthritis | Journal of Clinical Pharmacology | Q2 | 165 | 11.00 |
| 69. | Ng CM | 2005 | Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial | Journal of Clinical Pharmacology | Q2 | 164 | 9.65 |
| 70. | Moon YJ | 2008 | Quercetin pharmacokinetics in humans | Biopharmaceutics and Drug Disposition | Q2 | 164 | 11.71 |
| 71. | Mohamed AF | 2012 | Application of a loading dose of colistin methanesulfonate in critically ill patients: Population pharmacokinetics, protein binding, and prediction of bacterial kill | Antimicrobial Agents and Chemotherapy | Q1 | 163 | 16.3 |
| 72. | Yates CR | 2003 | The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients | Journal of Clinical Pharmacology | Q2 | 163 | 8.58 |
| 73. | Dowd NP | 2002 | Pharmacokinetics of tranexamic acid during cardiopulmonary bypass | Anesthesiology | Q1 | 161 | 8.05 |
| 74. | Mamiya K | 1998 | The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics | Epilepsia | Q1 | 161 | 6.71 |
| 75. | Kinzig-Schippers M | 2005 | Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? | Antimicrobial Agents and Chemotherapy | Q1 | 160 | 9.41 |
| 76. | Henningsson A | 2005 | Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel | Clinical Cancer Research | Q1 | 159 | 9.35 |
| 77. | Hesselink DA | 2004 | Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes | Clinical Pharmacology and Therapeutics | Q1 | 159 | 8.83 |
| 78. | Hsu A | 1998 | Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir | Clinical Pharmacology and Therapeutics | Q1 | 158 | 6.58 |
| 79. | Admiraal R | 2015 | Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis | The Lancet Haematology | Q1 | 156 | 22.29 |
| 80. | Roberts JA | 2011 | Vancomycin dosing in critically ill patients: Robust methods for improved continuous-infusion regimens | Antimicrobial Agents and Chemotherapy | Q1 | 154 | 14.00 |
| 81. | Nyakutira C | 2008 | High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe | European Journal of Clinical Pharmacology | Q2 | 154 | 11.00 |
| 82. | Smith PF | 2007 | Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid (bevirimat) against human immunodeficiency virus Infection | Antimicrobial Agents and Chemotherapy | Q1 | 154 | 10.27 |
| 83. | Birmingham PK | 1997 | Twenty-four-hour pharmacokinetics of rectal acetaminophen in children: An old drug with new recommendations | Anesthesiology | Q1 | 154 | 6.16 |
| 84. | Björkman S | 2012 | Population pharmacokinetics of recombinant factor VIII: The relationships of pharmacokinetics to age and body weight | Blood | Q1 | 153 | 15.3 |
| 85. | Peloquin CA | 2008 | Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis | Antimicrobial Agents and Chemotherapy | Q1 | 152 | 10.86 |
| 86. | Wright JG | 2001 | Estimation of glomerular filtration rate in cancer patients | British Journal of Cancer | Q1 | 151 | 7.19 |
| 87. | Dowell JA | 2004 | Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal | Journal of Clinical Pharmacology | Q2 | 150 | 8.33 |
| 88. | Wu L | 2002 | A joint model for nonlinear mixed-effects models with censoring and covariates measured with error, with application to AIDS studies | Journal of the American Statistical Association | Q1 | 150 | 7.50 |
| 89. | Anderson BJ | 1999 | Perioperative pharmacodynamics of acetaminophen analgesia in children | Anesthesiology | Q1 | 149 | 6.48 |
| 90. | Rosario M | 2015 | Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease | Alimentary Pharmacology and Therapeutics | Q1 | 146 | 20.86 |
| 91. | Widmer N | 2006 | Population pharmacokinetics of imatinib and the role of α1‐acid glycoprotein | British Journal of Clinical Pharmacology | Q1 | 145 | 9.06 |
| 92. | Bellnier DA | 2003 | Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients | Cancer Research | Q1 | 145 | 7.63 |
| 93. | Hayashi N | 2007 | A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab | British Journal of Clinical Pharmacology | Q1 | 143 | 9.53 |
| 94. | Ballantyne CM | 2015 | Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia | American Journal of Cardiology | Q1 | 142 | 20.29 |
| 95. | Kappelhoff BS | 2005 | Are adverse events of nevirapine and efavirenz related to plasma concentrations? | Antiviral Therapy | Q2 | 142 | 8.35 |
| 96. | Bajaj G | 2017 | Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients with Solid Tumors | CPT: Pharmacometrics and Systems Pharmacology | Q1 | 140 | 28.00 |
| 97. | Anderson BJ | 2000 | A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children | British Journal of Clinical Pharmacology | Q1 | 140 | 6.36 |
| 98. | Nation RL | 2017 | Dosing guidance for intravenous colistin in critically ill patients | Clinical Infectious Diseases | Q1 | 139 | 27.80 |
| 99. | Ariano RE | 2005 | Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia | Annals of Pharmacotherapy | Q1 | 137 | 8.06 |
| 100. | Mandema JW | 1996 | Characterization and validation of a pharmacokinetic model for controlled-release oxycodone | British Journal of Clinical Pharmacology | Q1 | 137 | 5.27 |
| Rank | First author | Year | Title | Journal | SCImago Journal Quartile 2021 | Number of citationsa | Citations per year |
|---|---|---|---|---|---|---|---|
| 1. | Admiraal R | 2015 | Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis | The Lancet Haematology | Q1 | 156 | 22.29 |
| 2. | Rosario M | 2015 | Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease | Alimentary Pharmacology and Therapeutics | Q1 | 146 | 20.86 |
| 3. | Ballantyne CM | 2015 | Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia | American Journal of Cardiology | Q1 | 142 | 20.29 |
| 4. | Bajaj G | 2017 | Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients with Solid Tumors | CPT: Pharmacometrics and Systems Pharmacology | Q1 | 140 | 28.00 |
| 5. | Nation RL | 2017 | Dosing guidance for intravenous colistin in critically ill patients | Clinical Infectious Diseases | Q1 | 139 | 27.80 |
| 6. | Blank A | 2016 | First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B | Journal of Hepatology | Q1 | 122 | 20.33 |
| 7. | Freshwater T | 2017 | Evaluation of dosing strategy for pembrolizumab for oncology indications | Journal for ImmunoTherapy of Cancer | Q1 | 121 | 24.20 |
| 8. | Bartelink IH | 2016 | Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis | The Lancet Haematology | Q1 | 112 | 18.67 |
| 9. | Xiao AJ | 2016 | Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia | Journal of Clinical Pharmacology | Q2 | 111 | 22.20 |
| 10. | Zhao X | 2017 | Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors | Annals of Oncology | Q1 | 111 | 18.50 |
| 11. | Admiraal R | 2017 | Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis | The Lancet Haematology | Q1 | 109 | 21.80 |
| 12. | Dunne MW | 2015 | Extended-duration dosing and distribution of dalbavancin into bone and articular tissue | Antimicrobial Agents and Chemotherapy | Q1 | 94 | 13.43 |
| 13. | Zhu M | 2016 | Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications | Clinical Pharmacokinetics | Q1 | 92 | 15.33 |
| 14. | Admiraal R | 2016 | Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation | Blood | Q1 | 90 | 15.00 |
| 15. | Namour F | 2015 | Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection | Clinical Pharmacokinetics | Q1 | 88 | 12.57 |
| 16. | Brandse JF | 2017 | A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease | Inflammatory Bowel Diseases | Q1 | 79 | 15.80 |
| 17. | De Grooth HJ | 2018 | Vitamin C Pharmacokinetics in Critically Ill Patients: A Randomized Trial of Four IV Regimens | Chest | Q1 | 78 | 19.50 |
| 18. | Eleveld DJ | 2018 | Pharmacokinetic–pharmacodynamic model for propofol for broad application in anaesthesia and sedation | British Journal of Anaesthesia | Q1 | 74 | 18.50 |
| 19. | Karaiskos I | 2015 | Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients | Antimicrobial Agents and Chemotherapy | Q1 | 74 | 10.57 |
| 20. | Varenhorst C | 2015 | Effect of genetic variations on ticagrelor plasma levels and clinical outcomes | European Heart Journal | Q1 | 74 | 10.57 |
| 21. | Baverel PG | 2018 | Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status | Clinical Pharmacology and Therapeutics | Q1 | 71 | 17.75 |
| 22. | Stroh M | 2017 | Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma | Clinical Pharmacology and Therapeutics | Q1 | 71 | 14.20 |
| 23. | Odore E | 2016 | Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies | Clinical Pharmacokinetics | Q1 | 63 | 10.50 |
| 24. | Chen N | 2015 | Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration | Cancer Chemotherapy and Pharmacology | Q1 | 61 | 8.71 |
| 25. | Coles LD | 2018 | Repeated-Dose Oral N-Acetylcysteine in Parkinson’s Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress | Journal of Clinical Pharmacology | Q2 | 60 | 15.00 |
| 26. | McCarthy JS | 2016 | A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study | Malaria Journal | Q1 | 60 | 10.00 |
| 27. | Jones AK | 2016 | Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis | AAPS Journal | Q1 | 60 | 10.00 |
| 28. | Størset E | 2015 | Improved tacrolimus target concentration achievement using computerized dosing in renal transplant recipients-a prospective, Randomized Study | Transplantation | Q1 | 60 | 8.57 |
| 29. | Sharma S | 2015 | Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn’s disease: Results from a randomized, multicenter, phase-3 study | Inflammatory Bowel Diseases | Q1 | 59 | 8.43 |
| 30. | Katsube T | 2017 | Pharmacokinetic/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function | Antimicrobial Agents and Chemotherapy | Q1 | 58 | 11.60 |
| 31. | Desai A | 2016 | Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi | Antimicrobial Agents and Chemotherapy | Q1 | 58 | 9.67 |
| 32. | Soy D | 2015 | Population pharmacokinetics of benznidazole in adult patients with Chagas disease | Antimicrobial Agents and Chemotherapy | Q1 | 58 | 8.29 |
| 33. | Le J | 2015 | Pharmacodynamic characteristics of nephrotoxicity associated with vancomycin use in children | Journal of the Pediatric Infectious Diseases Society | Q1 | 58 | 8.29 |
| 34. | Svensson EM | 2018 | The potential for treatment shortening with higher rifampicin doses: Relating drug exposure to treatment response in patients with pulmonary tuberculosis | Clinical Infectious Diseases | Q1 | 55 | 13.75 |
| 35. | Vet NJ | 2016 | Inflammation and organ failure severely affect midazolam clearance in critically ill children | American Journal of Respiratory and Critical Care Medicine | Q1 | 55 | 9.17 |
| 36. | Adane ED | 2015 | Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections | Pharmacotherapy | Q1 | 55 | 7.86 |
| 37. | Admiraal R | 2015 | Population Pharmacokinetic Modeling of Thymoglobulin® in Children Receiving Allogeneic-Hematopoietic Cell Transplantation: Towards Improved Survival Through Individualized Dosing | Clinical Pharmacokinetics | Q1 | 55 | 7.86 |
| 38. | Wise-Draper TM | 2017 | A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies | Targeted Oncology | Q1 | 54 | 10.80 |
| 39. | Dhoro M | 2015 | CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: Population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe | BMC Pharmacology and Toxicology | Q3 | 54 | 7.71 |
| 40. | Haas NB | 2019 | Autophagy inhibition to augment mTOR inhibition: A phase I/II trial of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinoma | Clinical Cancer Research | Q1 | 53 | 17.67 |
| 41. | Tamai T | 2017 | Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure–Response Analyses | Journal of Clinical Pharmacology | Q2 | 53 | 10.60 |
| 42. | Grau S | 2015 | Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis | Journal of Antimicrobial Chemotherapy | Q1 | 53 | 7.57 |
| 43. | Leroux S | 2015 | Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design | Clinical Pharmacokinetics | Q1 | 53 | 7.43 |
| 44. | Long-Boyle JR | 2015 | Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: A model-based dosing algorithm for personalized therapy and implementation into routine clinical use | Therapeutic Drug Monitoring | Q2 | 52 | 7.43 |
| 45. | Satia I | 2017 | Capsaicin-evoked cough responses in asthmatic patients: Evidence for airway neuronal dysfunction | Journal of Allergy and Clinical Immunology | Q1 | 51 | 10.20 |
| 46. | Milosheska D | 2016 | Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters | British Journal of Clinical Pharmacology | Q1 | 50 | 8.33 |
| 47. | De Cock PAJG | 2015 | Augmented renal clearance implies a need for increased amoxicillin-clavulanic acid dosing in critically ill children | Antimicrobial Agents and Chemotherapy | Q1 | 50 | 7.14 |
| 48. | Gupta N | 2015 | Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: A population pharmacokinetic analysis | British Journal of Clinical Pharmacology | Q1 | 50 | 7.14 |
| 49. | Andreu F | 2017 | A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach | Clinical Pharmacokinetics | Q1 | 49 | 9.80 |
| 50. | Chandorkar G | 2015 | Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections | Journal of Clinical Pharmacology | Q2 | 49 | 7.00 |
| 51. | Denti P | 2015 | Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania | PLoS ONE | Q1 | 49 | 7.00 |
| 52. | Kim H | 2018 | Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients | Clinical Pharmacology and Therapeutics | Q1 | 48 | 12.00 |
| 53. | Svensson RJ | 2018 | A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses | Clinical Pharmacology and Therapeutics | Q1 | 48 | 12.00 |
| 54. | Marostica E | 2015 | Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies | Cancer Chemotherapy and Pharmacology | Q1 | 48 | 6.86 |
| 55. | Hannivoort LN | 2015 | Development of an optimized pharmacokinetic model of dexmedetomidine using target-controlled infusion in healthy volunteers | Anesthesiology | Q1 | 48 | 6.86 |
| 56. | Vu T | 2017 | Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects | Pharmaceutical Research | Q2 | 47 | 9.40 |
| 57. | Brown K | 2017 | Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer | British Journal of Clinical Pharmacology | Q1 | 47 | 9.40 |
| 58. | Dolder PC | 2017 | Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects | Clinical Pharmacokinetics | Q1 | 47 | 9.40 |
| 59. | McCarthy JS | 2016 | Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers | Journal of Antimicrobial Chemotherapy | Q1 | 47 | 7.83 |
| 60. | Bustinduy AL | 2016 | Population pharmacokinetics and pharmacodynamics of praziquantel in Ugandan children with intestinal schistosomiasis: Higher dosages are required for maximal efficacy | mBio | Q1 | 47 | 7.83 |
| 61. | Zhao CY | 2016 | External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients | British Journal of Clinical Pharmacology | Q1 | 47 | 7.83 |
| 62. | Ternant D | 2015 | Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis | British Journal of Clinical Pharmacology | Q1 | 47 | 6.71 |
| 63. | Jaruratanasirikul S | 2015 | Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units | Clinical Pharmacology and Therapeutics | Q1 | 46 | 6.57 |
| 64. | Fanta S | 2015 | Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing | European Journal of Clinical Pharmacology | Q2 | 46 | 6.57 |
| 65. | Neely M | 2015 | Achieving target voriconazole concentrations more accurately in children and adolescents | Antimicrobial Agents and Chemotherapy | Q1 | 46 | 6.57 |
| 66. | Ulldemolins M | 2015 | Meropenem population pharmacokinetics in critically Ill patients with septic shock and continuous renal replacement therapy: Influence of residual diuresis on dose requirements | Antimicrobial Agents and Chemotherapy | Q1 | 46 | 6.57 |
| 67. | Klünder B | 2018 | Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials | Clinical Pharmacokinetics | Q1 | 45 | 11.25 |
| 68. | Kovalenko P | 2016 | Exploratory population PK analysis of Dupilumab, a fully human monoclonal antibody against IL-4Rα, in atopic dermatitis patients and normal volunteers | CPT: Pharmacometrics and Systems Pharmacology | Q1 | 45 | 7.50 |
| 69. | Frippiat F | 2015 | Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: The PROMESSE study | Journal of Antimicrobial Chemotherapy | Q1 | 45 | 6.43 |
| 70. | Parker SL | 2015 | Population pharmacokinetics of fosfomycin in critically ill patients | Antimicrobial Agents and Chemotherapy | Q1 | 45 | 6.43 |
| 71. | Janssen EJH | 2016 | Towards rational dosing algorithms for vancomycin in neonates and infants based on population pharmacokinetic modeling | Antimicrobial Agents and Chemotherapy | Q1 | 44 | 7.33 |
| 72. | Sloan DJ | 2015 | Pharmacodynamic modeling of bacillary elimination rates and detection of bacterial lipid bodies in sputum to predict and understand outcomes in treatment of pulmonary tuberculosis | Clinical Infectious Diseases | Q1 | 44 | 6.29 |
| 73. | Chatterjee M | 2017 | Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma | CPT: Pharmacometrics and Systems Pharmacology | Q1 | 43 | 8.60 |
| 74. | Savic RM | 2017 | Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure–response relations from two phase II clinical trials | Clinical Pharmacology and Therapeutics | Q1 | 43 | 8.60 |
| 75. | Gatault P | 2015 | Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule | mAbs | Q1 | 43 | 6.14 |
| 76. | Yoneyama K | 2018 | A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A | Clinical Pharmacokinetics | Q1 | 42 | 10.50 |
| 77. | Eleveld DJ | 2017 | An allometric model of remifentanil pharmacokinetics and pharmacodynamics | Anesthesiology | Q1 | 42 | 8.40 |
| 78. | Buurman DJ | 2015 | Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: Potential implications for dosing in clinical practice | Alimentary Pharmacology and Therapeutics | Q1 | 42 | 6.00 |
| 79. | Ding J | 2015 | A Population Pharmacokinetic Model of Valproic Acid in Pediatric Patients with Epilepsy: A Non-Linear Pharmacokinetic Model Based on Protein-Binding Saturation | Clinical Pharmacokinetics | Q1 | 42 | 6.00 |
| 80. | Abuhelwa AY | 2015 | Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states | Antimicrobial Agents and Chemotherapy | Q1 | 42 | 6.00 |
| 81. | Avedissian SN | 2017 | Augmented Renal Clearance Using Population-Based Pharmacokinetic Modeling in Critically Ill Pediatric Patients | Pediatric Critical Care Medicine | Q1 | 40 | 8.00 |
| 82. | Chirehwa MT | 2016 | Model-based evaluation of higher doses of rifampin using a semimechanistic model incorporating autoinduction and saturation of hepatic extraction | Antimicrobial Agents and Chemotherapy | Q1 | 40 | 6.67 |
| 83. | Gupta A | 2016 | Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer | British Journal of Clinical Pharmacology | Q1 | 40 | 6.67 |
| 84. | Brill MJ | 2015 | The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients before and One Year after Bariatric Surgery | Pharmaceutical Research | Q2 | 40 | 5.71 |
| 85. | Kovanda LL | 2016 | Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL study) | Antimicrobial Agents and Chemotherapy | Q1 | 39 | 6.50 |
| 86. | Rubino CM | 2015 | Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials | Antimicrobial Agents and Chemotherapy | Q1 | 39 | 5.57 |
| 87. | Panoilia E | 2015 | A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients | Cancer Chemotherapy and Pharmacology | Q1 | 39 | 5.57 |
| 88. | Boer H | 2015 | Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors | Annals of Oncology | Q1 | 39 | 5.57 |
| 89. | Mattioli F | 2016 | Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients | European Journal of Clinical Pharmacology | Q1 | 38 | 6.33 |
| 90. | Zhang J | 2015 | Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients | British Journal of Clinical Pharmacology | Q1 | 38 | 5.43 |
| 91. | Stockmann C | 2015 | Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates | Infectious Diseases and Therapy | Q1 | 38 | 5.43 |
| 92. | Andrews LM | 2018 | A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation | Clinical Pharmacokinetics | Q1 | 37 | 9.25 |
| 93. | Dhawan MS | 2017 | Differential toxicity in patients with and without DNA repair mutations: Phase I study of carboplatin and talazoparib in advanced solid tumors | Clinical Cancer Research | Q1 | 37 | 7.40 |
| 94. | Jullien V | 2017 | Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation | Journal of Antimicrobial Chemotherapy | Q1 | 37 | 7.40 |
| 95. | Neely M | 2016 | Accurately achieving target busulfan exposure in children and adolescents with very limited sampling and the bestdose software | Therapeutic Drug Monitoring | Q2 | 37 | 6.17 |
| 96. | Chiew AL | 2016 | Evidence for the changing regimens of acetylcysteine | British Journal of Clinical Pharmacology | Q1 | 37 | 6.17 |
| 97. | Quartino AL | 2016 | Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer | Cancer Chemotherapy and Pharmacology | Q1 | 37 | 6.17 |
| 98. | Vermeersch S | 2015 | Translational pharmacodynamics of calcitonin gene-related peptide monoclonal antibody LY2951742 in a capsaicin-induced dermal blood flow model | Journal of Pharmacology and Experimental Therapeutics | Q1 | 37 | 5.29 |
| 99. | Hoglund RM | 2015 | Artemether-lumefantrine co-administration with antiretrovirals: Population pharmacokinetics and dosing implications | British Journal of Clinical Pharmacology | Q1 | 37 | 5.29 |
| 100. | Liu XB | 2018 | Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients | British Journal of Clinical Pharmacology | Q1 | 36 | 7.20 |
| Information | Percentage of articles | |
| 1964-2021 (n= 21) | 2015-2021 (n = 23) | |
| Population Adult Paediatric Adult and paediatric | 100% (21) - - | 91.3% (21) 4.3% (1) 4.3% (1) |
| Disease Cancer Solid cancer Haematological cancera Combination of solid cancer and haematological cancer Others Rheumatoid Arthritis Neovascular age-related macular degeneration Hematopoietic cell transplantation | 90.5% (19) 73.7% (14) 15.8% (3) 10.5% (2) 9.5% (2) 50% (1) 50% (1) - | 87% (20) 80% (16) 15% (3) 5% (1) 13% (3) - - 100% (3) |
| Drugs Monoclonal antibody Protein kinase inhibitors Plant Alkaloid Antimetabolites Alkylating agents Other antineoplastic agents | 28.6% (6) 23.8% (5) 19% (4) 4.8% (1) 14.3% (3) 9.5% (2) | 39.1% (9) 26.1% (6) 4.3% (1) - 13% (3) 17.4% (4) |
| Information | Percentage of articles | |
| 1964-2021 (n= 12) | 2015-2021 (n =19) | |
| Populations Adult Paediatric Adult and paediatric | 100% (12) - | 68.4% (13) 26.3% (5) 5.3% (1) |
| Drugs Polymyxins Glycopeptides (Vancomycin, Oritavancin, dalbavancin) Meropenem Fluroquinolones Other antibacterials (Fosfomycin) Other cephalosporins and penems (Ceftolozane/tazobactam) Amoxicillin and beta lactamase inhibitors | 41.7% (5) 8.3% (1) 25% (3) 25% (3) - - - | 10.5% (2) 36.8% (7) 21.1% (4) 5.3% (1) 5.3% (1) 15.8% (3) 5.3% (1) |
| Information | Percentage of articles | |
| 1964-2021 (n=9) | 2015-2021 (n = 17) | |
| Populations Adult Paediatric Adult and paediatric | 80% (7) - 20% (2) | 71% (12) 12% (2) 17% (3) |
| Disease Transplantation Haemopoietic cell transplantation Renal transplant Kidney and heart transplant Inflammatory Bowel Disease Rheumatoid arthritis Mendelian interferonopathies Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic-uremic syndrome | 44.4% (4) 25% (1) 50% (2) 25% (1) 44.4% (4) 11.2% (1) - - | 47% (8) 50% (4) 50% (4) - 23% (4) 18% (3) 6% (1) 6% (1) |
| Drugs Selective immunosupressants Tumor necrosis factor- alpha inhibitors Calcineurin inhibitors | 33.3% (3) 44.4% (4) 22.2% (2) | 52.9% (9) 23.5% (4) 23.5% (4) |
DISCUSSION
To the best of our knowledge, this is the first study to summarise the top 100 most cited articles in the field of population PK, PD or PKPD modelling using the bibliometric approach. Moreover, we also showed how influential research landscape changed over time in the aforementioned field.
It has been suggested that articles that exceed the threshold of 100 citations can be considered “classic articles”, a sort of “milestones” in the development of a specific area.[22, 23] Since the number of citations for the 100 most cited articles for overall publications exceeds 100 citations, all the articles listed for overall publications can be considered “classic”. Knowledge and understanding of these classic papers can help guide education and provide additional insights into a better understanding of a specific field.[24] This study also found that during the recent years, there has been an increase in the number of publications published in Q1 journals, indicating that over time high impact journals became even more impactful.
This study found that the majority of the impactful articles used population PK modelling to analyse data. This is not surprising as PK data are in many cases easier to collect/measure and evaluate than PD data. Additionally, population PK is an established field with a specific regulatory guidance and many methodological articles on model development and diagnostics.[25, 26] PD results can, however, depend strongly on the disease, and the techniques for their analysis can thus be more difficult to unify. Still, recently, researchers started giving more emphasis to PD, especially to how PK affects PD; which is reflected also in a greater proportion of PKPD studies within the impactful articles. This may also be a consequence of regulatory recommendations, e.g. in 2016, the European Medicines Agency (EMA) published the "Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products[3] that focuses on the use of PKPD analyses to identify potentially efficacious dosing regimens.
Recently, in the top 100 most cited articles, there have been more studies looking at antibacterial and immunosuppressant classes of drugs (Figure 2). In the anti-infectives ATC classification, antimicrobials had the largest increase, possibly another consequence of the aforementioned EMA guidance[3] on the emerging research in this field. The increase was most prominent in special patient populations, where research was/is lacking the most, such as, the critically ill patients,[27, 28] extremely obese patients[29] or neonates.[30–32] In the chemotherapeutic and immunomodulating ATC class, most articles analysed PK(/PD) data of antineoplastic agents, which have remained the most cited over time. This may be due to cancer treatment being a continued important area of interest for the pharmaceutical industry, and one of the fastest growing areas in personalised medicines.[33] Over time, monoclonal antibodies (mAbs) have remained the most researched antineoplastic drugs in the top 100 most cited articles. This is in line with mAbs becoming a significant class of therapeutic drugs available;[34] to date, there are more than 100 mAbs approved by the US Food and Drug Administration.[35]
NONMEM® software was the most widely used software, which remained unchanged over the years. This is expected, given that NONMEM® was the first software package developed by Lewis Sheiner and Stuart Beal to handle complex PK calculations in the nonlinear mixed effect modelling approach.[36, 37] Furthermore, it is widely regarded as the gold standard in population pharmacokinetic-pharmacodynamic modelling.[38] Recently, the percentage of the influential articles that used NONMEM® increased further, despite other emerging software such as Pumas® which is gaining attention and slowly getting recognition.[39, 40]
We also found that recently, there has been an increase in the number of publications involving partnerships between developed and developing countries. One of the potential reasons could be the efforts that were made to promote global collaboration, such as the joint meetings of the Population Approach Group of Australia and New Zealand (PAGANZ, https://www.paganz.org/) with other population approach organizations groups such as the pharmacometrics research group in South Africa in 2002 and the group in Japan in 2006.[41] Moreover, an international collaboration between developed countries and developing countries in scientific research is an effective way to build scientific capacity and share resources.[42] Authors from US-based institutions were found to be most collaborative (Figure 4), probably a consequence of the large number of US-based researchers.
Funding support is an important part of research. Although majority of the 100 most cited articles were funded locally, there was a slight increase of articles that received international funding. This shows that with the availability of international funding support, countries that do not have significant national research budgets could perform highly cited population modelling studies and thus reach beyond national borders.
We also found that there were (mostly the same) top five journals that published 43-44% of all 100 most cited articles (Table 5), showing that if an article is published in one of these journals it likely has a higher probability of becoming an impactful, highly cited article. This may be valuable information for researchers who are newer in this field.
One of the limitations of this work may be the limited search involving only the Scopus database, while other conventional medicine databases, such as Web of Science, and Google Scholar, were not searched. Scopus database was selected as it provides about 20% more coverage than Web of Science, while Google Scholar can deliver results of inconsistent accuracy.[43, 44] Still, there is a possibility that some influential papers might have been overlooked. Additionally, manuscripts that did not report author-provided keywords, which were needed for the current analysis, had to be excluded as these were needed for the bibliometric analysis. Furthermore, as this study only focused on the 100 most cited articles, it should be kept in mind that the results/trends may not be representative of all published articles on population modelling. However, focusing on only these most impactful articles enabled us to confirm that each of the articles were indeed about our topic of interest, and to explore and compare the trends in more detail. One should also note that the citation count does not directly indicate the quality of an article but rather only enables a quantitative evaluation of the scientific impact of an article in a specified research field. Additionally, because citations accumulate over time, papers published earlier understandably have a higher chance of receiving more citations than those published later, making this an important consideration when using the citation count to rank individual papers; we tried to address this by calculating the number of citations per year (since an article has been published) (Supplementary Tables 1 and 2).
We hope that our work will encourage research on topics and/or populations that are currently less represented in such impactful highly cited articles. For example, as the majority of the impactful studies described in the top 100 most cited articles were population PK studies, the field would benefit in focusing (even more) on population PD or PKPD studies, to e.g. increase knowledge of the drug effects and their relationship with the PK too. Although the trends of highly cited papers appear to be slowly improving when involving the paediatric population, there is much room for research and improvement in this special population. It is likely, however, that the current most popular topics in this field will continue to gain attention and influence in the research community in the future.
CONCLUSION
We bibliometrically explored the 100 most cited articles in the population PK, PD or PKPD modelling and the research trends in this field over time. Majority of the studies described in the 100 most cited articles were published by top five journals and were population PK modelling studies looking into immunosuppressant or antibacterial drug data, involving adult population, and using NONMEM® for the analyses. There was a positive shift from studies using PK only models to PKPD models in the recent years. Apart from that no other metric that we looked at changed dramatically in the 100 most cited articles in the recent years, compared to from inception.
Conflict of Interest
The authors declare that there is no conflict of interest.
Author Contributions
NM performed the analysis and wrote the manuscript. HZ designed the research and reviewed the manuscript. EG designed the research, wrote, and reviewed the manuscript.
